We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study
Read MoreHide Full Article
Spectrum Pharmaceuticals, Inc. announced positive data from a phase III study, ADVANCE, evaluating its lead pipeline candidate, Rolontis, for management of chemotherapy-induced neutropenia in patients with early-stage breast cancer. The candidate demonstrated non-inferiority to Amgen Inc.’s (AMGN - Free Report) Neulasta in improving duration of severe neutropenia.
Shares of Spectrum Pharma have skyrocketed 314.8% in the past year, significantly outperforming the industry’s gain of 2.8%.
The company is evaluating Rolontis in two phase III studies – ADVANCE and RECOVER – in early-stage breast cancer patients.
The ADVANCE study compared Rolontis to Neulasta for management of chemotherapy-induced neutropenia in breast cancer patients who received docetaxel and cyclophosphamide chemotherapy every 21 days.
With the completion of enrollment in RECOVER study, announced in the press release, Spectrum Pharma is on track to file a biologics license application seeking approval of Rolontis for management of neutropenia in the fourth quarter of 2018.
Apart from Rolontis, the company is developing Qapzola for treating non-muscle invasive bladder cancer and poziotinib in non-small cell lung cancer patients and breast cancer.
In October 2017, Spectrum announced encouraging preliminary data on poziotinib from phase II NSCLC study in patients who have exon 20 insertion mutations in EGFR.
However, Spectrum Pharma’s product sales from its six marketed products have been lacklusterin the last six months due to intense competition. This keeps investors focused on pipeline development.
Anthera’s loss estimates narrowed from $3.09 to $3.02 for 2017 and from $2.31 to $2.10 in the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 5.52%.
Exelixis’ earnings estimates increased from 73 cents to 77 cents for 2018 over the last 30 days. The company delivered a positive earnings surprise in all the trailing four quarters with an average beat of 572.92%. The stock has returned 42.1% in the past year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study
Spectrum Pharmaceuticals, Inc. announced positive data from a phase III study, ADVANCE, evaluating its lead pipeline candidate, Rolontis, for management of chemotherapy-induced neutropenia in patients with early-stage breast cancer. The candidate demonstrated non-inferiority to Amgen Inc.’s (AMGN - Free Report) Neulasta in improving duration of severe neutropenia.
Shares of Spectrum Pharma have skyrocketed 314.8% in the past year, significantly outperforming the industry’s gain of 2.8%.
The company is evaluating Rolontis in two phase III studies – ADVANCE and RECOVER – in early-stage breast cancer patients.
The ADVANCE study compared Rolontis to Neulasta for management of chemotherapy-induced neutropenia in breast cancer patients who received docetaxel and cyclophosphamide chemotherapy every 21 days.
With the completion of enrollment in RECOVER study, announced in the press release, Spectrum Pharma is on track to file a biologics license application seeking approval of Rolontis for management of neutropenia in the fourth quarter of 2018.
Apart from Rolontis, the company is developing Qapzola for treating non-muscle invasive bladder cancer and poziotinib in non-small cell lung cancer patients and breast cancer.
In October 2017, Spectrum announced encouraging preliminary data on poziotinib from phase II NSCLC study in patients who have exon 20 insertion mutations in EGFR.
However, Spectrum Pharma’s product sales from its six marketed products have been lacklusterin the last six months due to intense competition. This keeps investors focused on pipeline development.
Spectrum Pharmaceuticals, Inc. Price
Spectrum Pharmaceuticals, Inc. Price | Spectrum Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Spectrum Pharma carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the pharma sector include Anthera Pharmaceuticals, Inc. (ANTH - Free Report) and Exelixis, Inc. (EXEL - Free Report) . Both the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Anthera’s loss estimates narrowed from $3.09 to $3.02 for 2017 and from $2.31 to $2.10 in the last 30 days. The company came up with a positive earnings surprise in three of the trailing four quarters with an average beat of 5.52%.
Exelixis’ earnings estimates increased from 73 cents to 77 cents for 2018 over the last 30 days. The company delivered a positive earnings surprise in all the trailing four quarters with an average beat of 572.92%. The stock has returned 42.1% in the past year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>